Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTAJU0S)

DTT Name Interleukin 2 receptor (IL2R)
Synonyms
p64; gammaC; Interleukin2 receptor subunit gamma; Interleukin-2 receptor subunit gamma; IL2R subunit gamma; IL2 receptor subunit gamma; IL-2RG; IL-2R subunit gamma; IL-2R; IL-2 receptor subunit gamma; Cytokine receptor common subunit gamma; CD132
Gene Name IL2R
DTT Type
Successful target
 [1]
BioChemical Class
Cytokine receptor
UniProt ID
NOUNIPROTAC
TTD ID
T20710
Function Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15. Common subunit for the receptors for a variety of interleukins.
KEGG Pathway
Cytokine-cytokine receptor interaction (hsa04060 )
Endocytosis (hsa04144 )
PI3K-Akt signaling pathway (hsa04151 )
Jak-STAT signaling pathway (hsa04630 )
Hematopoietic cell lineage (hsa04640 )
Measles (hsa05162 )
HTLV-I infection (hsa05166 )
Reactome Pathway
Interleukin-7 signaling (R-HSA-1266695 )
G beta (R-HSA-392451 )
Interleukin-2 signaling (R-HSA-451927 )
RAF/MAP kinase cascade (R-HSA-5673001 )
Interleukin receptor SHC signaling (R-HSA-912526 )
GPVI-mediated activation cascade (R-HSA-114604 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Denileukin diftitox DMMHR1U Epithelial ovarian cancer 2B5D Approved [1]
------------------------------------------------------------------------------------
1 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
ALKS 4230 DME3ZYC Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
------------------------------------------------------------------------------------
1 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ro26-4550 DMGL7TM Discovery agent N.A. Investigative [3]
------------------------------------------------------------------------------------

References

1 Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69.
2 ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020 Apr;8(1):e000673.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2297).